Article

AJMC® in the Press, March 1, 2019

Author(s):

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

An article from The American Journal of Managed Care®’s sister site The Center for Biosimilars® was highlighted by OBR Oncology’s daily newsfeed. The article, “Ahead of FDA Decision on its Pegfilgrastim Biosimilar, Sandoz Sues Amgen,” reported on Sandoz filing suit against Amgen, asking the United States District Court for the Northern District of California for a declaratory judgment of patent noninfringement and invalidity.

Related Videos
John Barkett, MBA
1 expert in this video
Dr Gerard Criner
Emma Achola-Kothari, PhD
Dr Margrit Wiesendanger
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Women in science | Image Credit: © metamorworks-stock.adobe.com.jpeg
May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw
Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Adolescent patients were more likely to be most bothered by feelings of anxiety or atopic dermatitis affecting their daily activities. | Image Credit: InfiniteStudio - stock.adobe.com
May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor
The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Marina De Brot, MD, PhD| Image credit: AC Camargo Cancer Center
May 22nd 2025

AI Can Boost Accuracy When Classifying HER2-Low, HER2-Ultralow Breast Cancers, Findings Show

Mary Caffrey
Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.
In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo